Aethlon Medical (NASDAQ:AEMD) Shares Pass Above 200 Day Moving Average – Should You Sell?

Shares of Aethlon Medical, Inc. (NASDAQ:AEMD) crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $2.63 and traded as high as $2.77. Aethlon Medical shares last traded at $2.21, with a volume of 875,634 shares.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research note on Monday, April 20th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Aethlon Medical currently has a consensus rating of “Reduce”.

Aethlon Medical Trading Down 24.8%

The stock has a market capitalization of $3.47 million, a P/E ratio of -0.15 and a beta of 1.50. The stock has a 50 day moving average of $2.24 and a 200-day moving average of $2.63.

Institutional Investors Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities and Exchange Commission. 1.99% of the stock is currently owned by institutional investors.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.